What is⁣ Pin1 and Why is it important in Pancreatic ⁢Cancer?

Pin1 is an⁣ oncogenic enzyme, meaning it promotes cancer ⁣growth. It is frequently overexpressed in various tumors, including pancreatic cancer. Its role involves stabilizing other proteins that drive tumor growth and survival.Conventional cancer​ therapies often focus on blocking the activity of these proteins. However, this approach can lead to resistance as cancer cells adapt. The new research focuses on a different strategy:⁤ degrading Pin1 itself, effectively removing it ​from the​ system.

the “Molecular Crowbar” Approach

Researchers at the University of California, Riverside⁢ (UCR) developed a ⁤novel strategy ​to ⁢degrade⁢ Pin1. They designed compounds that act as a ⁣”molecular crowbar,” binding to Pin1 and destabilizing its structure.this destabilization​ leads to the enzyme’s ⁣degradation within the cell.

This approach is ‍significant as it doesn’t just target ⁤cancer cells directly.It also addresses tumor-supporting cells, such as cancer-associated fibroblasts and macrophages, where Pin1 is also active. This is crucial because the fibrous⁣ tumor microenvironment in​ pancreatic cancer often contributes to⁤ treatment resistance.

Collaboration Between UCR​ and City ‍of ‌Hope

The UCR team, led by Maurizio pellecchia, collaborated with a team at City⁢ of ​Hope, led ​by Mustafa ‌Raoof, to further test these Pin1 degraders in pancreatic and ⁢gastrointestinal cancers. The goal is to develop a new class of therapeutics ⁤that can “remove” harmful proteins rather ⁢than simply ⁣blocking them.

This collaboration was facilitated by a⁣ shared U54⁢ grant from the National cancer Institute (NCI), part of the‍ National institutes of Health (NIH).

Key Findings and⁢ Potential Benefits

The research builds upon previous work ‍where UCR ‌researchers successfully developed the initial Pin1 degradation strategy. this latest phase focuses on validating the approach in more‍ complex⁢ models of​ pancreatic and gastrointestinal cancers.

Degrading Pin1 offers several potential advantages:

• Overcoming ⁤Resistance: ‌ By removing the⁤ enzyme, the approach may bypass resistance mechanisms that⁣ develop‍ with traditional inhibitors.
• Targeting the Tumor Microenvironment: Addressing Pin1 in supporting cells could​ disrupt⁣ the environment ⁢that fuels tumor growth.
• Novel ⁣therapeutic Class: This‍ research contributes to​ a growing field of “degrader” therapeutics, offering a new way to combat​ cancer.

Timeline and Next Steps

2023: UCR researchers develop the initial​ “molecular crowbar” strategy to degrade Pin1.

Present: Collaboration between ⁢UCR and ‌City of Hope ⁣to test ⁣Pin1 degraders in pancreatic⁣ and gastrointestinal ⁤cancer models.

Future: Further preclinical studies, followed by potential​ clinical trials to evaluate ⁢the safety ‍and efficacy of these degraders in humans.